AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18722479 — intervention group
Group type: EXPERIMENTAL
Intervention: Size Cue (SC)
Number of subjects: 40
Study 17002630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype PRISM Chagas assay
Number of subjects: 8288
Study 11890955 — intervention group
Group type: EXPERIMENTAL
Intervention: Orosensory stimulation with lipid and carbohydrate stimuli (butter, UFA margarine, jelly)
Number of subjects: 16
Study 11890955 — intervention group
Group type: EXPERIMENTAL
Intervention: Orosensory stimulation with cracker and butter
Number of subjects: 16
Study 11890955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral stimulation)
Number of subjects: 16
Study 9527732 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (M)
Number of subjects: 40
Study 9527732 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 40
Study 7885818 — intervention group
Group type: EXPERIMENTAL
Intervention: Iconic cues (pure tones with frequency identical to the signal)
Number of subjects: 0
Study 7885818 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex cues (complex tones with a missing fundamental equal to the signal)
Number of subjects: 0
Study 7885818 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative cues (pure tones with a certain frequency relation to the signal)
Number of subjects: 0
Study 7885818 — intervention group
Group type: COMPARATOR
Intervention: No-cue condition
Number of subjects: 0
Study 7885818 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex-cue condition
Number of subjects: 0
Study 7885818 — intervention group
Group type: EXPERIMENTAL
Intervention: Iconic and relative cues
Number of subjects: 0
Study 2381005 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous (Seldinger wire) technique
Number of subjects: 327
Study 2381005 — intervention group
Group type: COMPARATOR
Intervention: Open peritoneal lavage technique
Number of subjects: 327
Study 364763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 0
Study 364763 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 55,897
Number of subjects: 0
Study 29723512 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 461
Study 29723512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 29723512 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 461
Study 26829012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0
Study 26829012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel with G-CSF
Number of subjects: 0
Study 26829012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel without G-CSF
Number of subjects: 0
Study 26829012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NLR and grade ≥3 neutropenia
Number of subjects: 0
Study 26829012 — intervention group
Group type: EXPERIMENTAL
Intervention: High NLR and no grade ≥3 neutropenia
Number of subjects: 0
Study 24251969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (1000 mg single administration)
Number of subjects: 97
Study 24251969 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (200 mg daily for 3 months)
Number of subjects: 97
Study 24251969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 24007976 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 11557
Study 24007976 — intervention group
Group type: COMPARATOR
Intervention: Early-generation DES
Number of subjects: 11557
Study 24007976 — intervention group
Group type: COMPARATOR
Intervention: Newer-generation DES
Number of subjects: 11557
Study 20074724 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroid embolization
Number of subjects: 36
Study 20074724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 18838524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (omega-3 fatty acids)
Number of subjects: 3
Study 16191850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short contact dithranol treatment
Number of subjects: 250
Study 16191850 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 250
Study 16191850 — intervention group
Group type: COMPARATOR
Intervention: Inpatient dithranol treatment
Number of subjects: 250
Study 12577228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 12577228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine
Number of subjects: 0
Study 12577228 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine combined with bolus or infusional 5‐fluorouracil, capecitabine, metalloproteinase inhibitors, or FTI tipifarnib
Number of subjects: 0
Study 9578187 — intervention group
Group type: EXPERIMENTAL
Intervention: MKS492 40 mg
Number of subjects: 18
Study 9578187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9578187 — intervention group
Group type: EXPERIMENTAL
Intervention: MKS492 20 mg
Number of subjects: 18
Study 7713834 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 76
Study 7713834 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 76
Study 2547540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Hyalgan (HA, Na-hyaluronate, 20 mg/2 ml)
Number of subjects: 16
Study 2547540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study 13501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 0
Study 13501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 0
Study 13501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 0
Study 13501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 13501 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 0
Study 30541365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan fasting
Number of subjects: 44
Study 28342775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash and Counseling (treatment group)
Number of subjects: 456
Study 28342775 — intervention group
Group type: COMPARATOR
Intervention: Agency-based care (control group)
Number of subjects: 456
Study 26040586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 9
Study 26040586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 9
Study 26040586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 9
Study 26040586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22762200 — intervention group
Group type: EXPERIMENTAL
Intervention: Short time (overnight) smoking abstinence
Number of subjects: 45
Study 22762200 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg) after overnight smoking abstinence
Number of subjects: 45
Study 22762200 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 45
Study 21070216 — intervention group
Group type: EXPERIMENTAL
Intervention: Good seizure control
Number of subjects: 0
Study 21070216 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of depression and fewer adverse treatment effects at 4 years
Number of subjects: 0
Study 21070216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair/poor health perception, presence of depression, reduced sense of mastery, and more adverse treatment effects at follow-up
Number of subjects: 0
Study 21070216 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions to increase self-mastery, reduce health concerns, treat depression, and promote positive adjustment
Number of subjects: 0
Study 19756816 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal pacing with dynamic atrial overdrive (DAO) and AV delay optimization
Number of subjects: 25
Study 19756816 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacing with dynamic atrial overdrive (DAO) and AV delay optimization
Number of subjects: 25
Study 17570430 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group (aspirin treatment initiation 24 hours after discontinuing bladder irrigation)
Number of subjects: 120
Study 17570430 — intervention group
Group type: COMPARATOR
Intervention: Late treatment group (aspirin treatment initiation 3 weeks after surgery)
Number of subjects: 120
Study 17570430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 14967093 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic review or RCT (level I)
Number of subjects: 980
Study 14967093 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-experimental or consensus evidence (level II)
Number of subjects: 980
Study 14967093 — intervention group
Group type: EXPERIMENTAL
Intervention: No good evidence (level III)
Number of subjects: 980
Study 14967093 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique diagnosis-treatment pairs analysis
Number of subjects: 980
Study 11285108 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer use with weekly nurse training
Number of subjects: 0
Study 11285108 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly training with a significant other
Number of subjects: 0
Study 11285108 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer use alone
Number of subjects: 0
Study 11285108 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computer terminal use)
Number of subjects: 0
Study 9602225 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg o.d.
Number of subjects: 27
Study 9602225 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 8066906 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking advice
Number of subjects: 0
Study 8066906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manuals
Number of subjects: 0
Study 8066906 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of smoking dependent chemical factors
Number of subjects: 0
Study 8066906 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial methods
Number of subjects: 0
Study 30452609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 129
Study 30452609 — intervention group
Group type: EXPERIMENTAL
Intervention: resting instantaneous wave‐free ratio (iFR)
Number of subjects: 129
Study 30452609 — intervention group
Group type: EXPERIMENTAL
Intervention: resting Pd/Pa
Number of subjects: 129
Study 30452609 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR ≤0.80
Number of subjects: 129
Study 30452609 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR ≤0.89
Number of subjects: 129
Study 30452609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd/Pa ≤0.92
Number of subjects: 129
Study 27832796 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypertension
Number of subjects: 792
Study 27832796 — intervention group
Group type: COMPARATOR
Intervention: No antecedent hypertension
Number of subjects: 792
Study 27832796 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hypertension and no hypertension)
Number of subjects: 792
Study 25296147 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Exercise (twice a week for 15 minutes over 10 weeks)
Number of subjects: 30
Study 25296147 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Exercise
Number of subjects: 30
Study 22858219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg)
Number of subjects: 51
Study 22858219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 51
Study 21138634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogue therapy (early stage)
Number of subjects: 348
Study 21138634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogue therapy (middle stage)
Number of subjects: 348
Study 21138634 — intervention group
Group type: COMPARATOR
Intervention: Control group (early stage)
Number of subjects: 348
Study 21138634 — intervention group
Group type: COMPARATOR
Intervention: Control group (middle stage)
Number of subjects: 348
Study 19910033 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (75-375 mg sc, q2 or q4 wk)
Number of subjects: 627
Study 19910033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 16546494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medications (oral laxative, digestant, defoaming agent)
Number of subjects: 236
Study 16546494 — intervention group
Group type: COMPARATOR
Intervention: NPO (nothing by mouth)
Number of subjects: 236
Study 12694432 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (n=24)
Number of subjects: 39
Study 12694432 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control, n=15)
Number of subjects: 39
Study 11127527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (endoscopy, chest radiography, abdominal ultrasound, CT pelvis)
Number of subjects: 1054
Study 11127527 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed follow-up concepts (risk-adaption)
Number of subjects: 1054
Study 11127527 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended German follow-up guideline
Number of subjects: 1054
Study 9339980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 51
Study 9339980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 51
Study 9339980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8382428 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing
Number of subjects: 350
Study 8382428 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed glottis technique
Number of subjects: 350
Study 8382428 — intervention group
Group type: EXPERIMENTAL
Intervention: Open glottis technique
Number of subjects: 350
Study 8382428 — intervention group
Group type: COMPARATOR
Intervention: Forced pushing
Number of subjects: 350
Study 3535127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg once daily
Number of subjects: 528
Study 3535127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg twice daily
Number of subjects: 528
Study 3535127 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 2 tablets twice a day
Number of subjects: 528
Study 31904681 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Number of subjects: 103
Study 31904681 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy
Number of subjects: 103
Study 31904681 — intervention group
Group type: COMPARATOR
Intervention: 14-day triple therapy
Number of subjects: 103
Study 29526681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration categories (≤5.5, 6-6.5, 7-7.5, 8-8.5, and ≥9 hours)
Number of subjects: 2848
Study 29526681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 2848
Study 27861400 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-kVp protocol
Number of subjects: 100
Study 27861400 — intervention group
Group type: EXPERIMENTAL
Intervention: i-100-kVp protocol (100-kVp with hybrid iterative reconstruction)
Number of subjects: 100
Study 27861400 — intervention group
Group type: COMPARATOR
Intervention: 120-kVp protocol
Number of subjects: 100
Study 27861400 — intervention group
Group type: EXPERIMENTAL
Intervention: i-100-kVp protocol
Number of subjects: 100
Study 24894651 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 1201081 0.32 mg/kg subcutaneously weekly plus cetuximab (combination)
Number of subjects: 0
Study 24894651 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab monotherapy (control)
Number of subjects: 0
Study 21840917 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot‐assisted therapy
Number of subjects: 20
Study 21840917 — intervention group
Group type: COMPARATOR
Intervention: Dose‐matched active control therapy
Number of subjects: 20
Study 19672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 15
Study 19672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 15
Study 19672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg + Rabeprazole 10 mg
Number of subjects: 15
Study 19672708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg + Rabeprazole 40 mg
Number of subjects: 15
Study 19672708 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 15
Study 18443775 — intervention group
Group type: EXPERIMENTAL
Intervention: FSTIR images
Number of subjects: 24
Study 18443775 — intervention group
Group type: COMPARATOR
Intervention: FSE T2‐W images
Number of subjects: 24
Study 15915935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride treatment for 3 months
Number of subjects: 0
Study 15915935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15915935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride treatment
Number of subjects: 0
Study 11821508 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate cream (40 g per day)
Number of subjects: 341
Study 11821508 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (0.5 mg/kg/day for moderate disease and 1 mg/kg/day for extensive disease)
Number of subjects: 341
Study 9951426 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice a day for 5 days)
Number of subjects: 12
Study 9951426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (6 mg oral dose)
Number of subjects: 12
Study 9951426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7752176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 23
Study 7752176 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 60 mg twice daily
Number of subjects: 23
Study 1979363 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 926
Study 1979363 — intervention group
Group type: COMPARATOR
Intervention: Formula only
Number of subjects: 926
Study 1979363 — intervention group
Group type: COMPARATOR
Intervention: Formula plus breast milk
Number of subjects: 926
Study 1979363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurised donor milk
Number of subjects: 926
Study 1979363 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral feeding in formula-fed infants
Number of subjects: 926
Study 1979363 — intervention group
Group type: COMPARATOR
Intervention: Exclusive formula feeding
Number of subjects: 926
Study 1979363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in confirmed cases of necrotising enterocolitis
Number of subjects: 926
Study 6993446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg/day)
Number of subjects: 235
Study 6993446 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (18.6 mg/day)
Number of subjects: 235
Study 6993446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 6993446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 235
Study 6993446 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 235
Study 31532960 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (400, 800, or 1200 mg twice daily)
Number of subjects: 161
Study 31532960 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir (standard dose)
Number of subjects: 161
Study 31532960 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 161
Study 31532960 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 161
Study 28056541 — intervention group
Group type: EXPERIMENTAL
Intervention: User-controlled text messaging intervention
Number of subjects: 64
Study 28056541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no texting intervention)
Number of subjects: 64
Study 26369656 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA10
Number of subjects: 30
Study 26369656 — intervention group
Group type: COMPARATOR
Intervention: Eprex
Number of subjects: 30
Study 26369656 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA10 and Eprex
Number of subjects: 30
Study 23710811 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 62
Study 23710811 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 62
Study 21836117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-risk social/cognitive intervention delivered by public health nurses (4 visits)
Number of subjects: 235
Study 21836117 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary public health services (control group)
Number of subjects: 235
Study 19767089 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39)
Number of subjects: 79
Study 19767089 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 3.5 g/m(2) on day 1 (n=40)
Number of subjects: 79
Study 17420402 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 331
Study 17420402 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 331
Study 17420402 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 331
Study 17420402 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 331
Study 14722639 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated catheter
Number of subjects: 180
Study 14722639 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine and silver sulfadiazine-coated catheter
Number of subjects: 180
Study 11478138 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH agonist combined with tamoxifen
Number of subjects: 0
Study 11478138 — intervention group
Group type: COMPARATOR
Intervention: LH-RH agonist alone
Number of subjects: 0
Study 9409569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver (intermittent for 20 minutes with a 5-minute clamp-free interval)
Number of subjects: 100
Study 9409569 — intervention group
Group type: COMPARATOR
Intervention: Control (no Pringle maneuver)
Number of subjects: 100
Study 8009000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (Pyr)
Number of subjects: 554